<code id='2C0D7396E7'></code><style id='2C0D7396E7'></style>
    • <acronym id='2C0D7396E7'></acronym>
      <center id='2C0D7396E7'><center id='2C0D7396E7'><tfoot id='2C0D7396E7'></tfoot></center><abbr id='2C0D7396E7'><dir id='2C0D7396E7'><tfoot id='2C0D7396E7'></tfoot><noframes id='2C0D7396E7'>

    • <optgroup id='2C0D7396E7'><strike id='2C0D7396E7'><sup id='2C0D7396E7'></sup></strike><code id='2C0D7396E7'></code></optgroup>
        1. <b id='2C0D7396E7'><label id='2C0D7396E7'><select id='2C0D7396E7'><dt id='2C0D7396E7'><span id='2C0D7396E7'></span></dt></select></label></b><u id='2C0D7396E7'></u>
          <i id='2C0D7396E7'><strike id='2C0D7396E7'><tt id='2C0D7396E7'><pre id='2C0D7396E7'></pre></tt></strike></i>

          Home / hotspot / focus

          focus


          focus

          author:leisure time    Page View:58

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In